What does the Supriya Lifescience Limited (SUPRIYA) stock page cover?

Supriya Lifescience Limited on Anvest includes delayed price context, valuation ratios, a one-year price range, and section-level research data when available.

What are the current headline metrics for SUPRIYA?

Supriya Lifescience Limited is currently shown with a delayed price near ₹847.3, P/E 34.37.

Does the SUPRIYA page provide investment advice?

No. The SUPRIYA page is built for research, comparison, and planning. It does not publish buy, sell, or hold recommendations.

Stocks›Healthcare

Watch Alert

Supriya Lifescience Limited

SUPRIYA · NSE · Healthcare · As of 30 Oct 2026Delayed / Sandbox EOD Data

₹847.30

−₹22.00 (−2.53%)(1D)

₹545.5052 Week Range₹1,085.00

Anvest Score

72/100

Valuation

15/100

Quality

85/100

Growth

94/100

Health

100/100

Momentum

73/100

Valuation
15
Quality
85
Growth
94
Health
100
Momentum
73

Loading company profile…

More Page Context

Research at a glance

Supriya Lifescience Limited with delayed price, financials, ownership context, and peer links.

Latest price

₹847.3

Market cap

₹6,817 Cr

P/E ratio

34.37

P/B ratio

5.69

Dividend yield

Not available

ROE

Not available

RSI 14

44.23

1Y return

Not available

Supriya Lifescience Limited FAQs

3 topics

Expand

Stocks›Healthcare

Watch Alert

Supriya Lifescience Limited

SUPRIYA · NSE · Healthcare · As of 30 Oct 2026Delayed / Sandbox EOD Data

₹847.30

−₹22.00 (−2.53%)(1D)

₹545.5052 Week Range₹1,085.00

Anvest Score

72/100

Valuation

15/100

Quality

85/100

Growth

94/100

Health

100/100

Momentum

73/100

Valuation
15
Quality
85
Growth
94
Health
100
Momentum
73

AI Company ProfileSign in to generate AI briefing

AI Snapshot

Supriya Lifescience Limited is a prominent Indian manufacturer of Active Pharmaceutical Ingredients (APIs) with a strong focus on research and development. The company operates globally, supplying its products to various pharmaceutical companies worldwide, establishing itself as a key player in the API segment.

BiotechnologyGlobal FootprintFounded:1990CEO/MD:Satish Waman WaghHQ:Mumbai, Maharashtra

Business profile as of 2026-08-25

Business at a Glance

Supriya Lifescience has scaled its manufacturing facilities, with multiple blocks established over the years.
The company highlights a significant export presence, aiming for balanced customer concentration and expanding into new geographies with existing and new products.

Revenue growth: +18.9%FY26 growth+21.6%3Y CAGR
EPS growth: +11.3%FY26 growth+32.5%3Y CAGR
CFO / PAT: 0.89×FY26

What Looks Strong

GrowthRevenue and net profit grew at +22% and +32% 3Y CAGR.
QualityQuality score is supported by healthy return on equity (ROE 17.5%).
MarketShareholder returns have comfortably outpaced the Nifty 500 benchmark over the 3-year period.

What to Watch

ValuationShare price has risen ~52% annualised over three years against ~32% profit growth, increasing valuation sensitivity to a growth slowdown.

Reports a single operating segment in its results filings.
Supriya Lifescience manufactures and supplies a diverse range of Active Pharmaceutical Ingredients (APIs) across various therapeutic segments.
They generate revenue by selling these APIs to pharmaceutical companies for use in their finished drug formulations, leveraging their R&D capabilities and manufacturing facilities.

FY26 (standalone): revenue ₹828 cr, up 19% from ₹696 cr in FY25; net profit ₹209 cr, up 11% from ₹188 cr in FY25.
FY26 (standalone): operating cash flow ₹186 cr (0.9× net profit); debt/equity 0.00×.
Latest quarter to Jun 2026 (standalone): revenue ₹190 cr (up 31% year on year); net profit ₹24.0 cr.

The company has historically had a high share of revenue from its top 10 customers, though it plans to reduce…
Export sales as a percentage of revenue have shown fluctuations

Loading company profile…

More Page Context

Research at a glance

Supriya Lifescience Limited with delayed price, financials, ownership context, and peer links.

Latest price

₹847.3

Market cap

₹6,817 Cr

P/E ratio

34.37

P/B ratio

5.69

Dividend yield

Not available

ROE

Not available

RSI 14

44.23

1Y return

Not available

Supriya Lifescience Limited FAQs

3 topics

Expand

AI Company ProfileSign in to generate AI briefing

AI Snapshot

Supriya Lifescience Limited is a prominent Indian manufacturer of Active Pharmaceutical Ingredients (APIs) with a strong focus on research and development. The company operates globally, supplying its products to various pharmaceutical companies worldwide, establishing itself as a key player in the API segment.

BiotechnologyGlobal FootprintFounded:1990CEO/MD:Satish Waman WaghHQ:Mumbai, Maharashtra

Business profile as of 2026-08-25

Business at a Glance

Supriya Lifescience has scaled its manufacturing facilities, with multiple blocks established over the years.
The company highlights a significant export presence, aiming for balanced customer concentration and expanding into new geographies with existing and new products.

Revenue growth: +18.9%FY26 growth+21.6%3Y CAGR
EPS growth: +11.3%FY26 growth+32.5%3Y CAGR
CFO / PAT: 0.89×FY26

What Looks Strong

GrowthRevenue and net profit grew at +22% and +32% 3Y CAGR.
QualityQuality score is supported by healthy return on equity (ROE 17.5%).
MarketShareholder returns have comfortably outpaced the Nifty 500 benchmark over the 3-year period.

What to Watch

ValuationShare price has risen ~52% annualised over three years against ~32% profit growth, increasing valuation sensitivity to a growth slowdown.

Reports a single operating segment in its results filings.
Supriya Lifescience manufactures and supplies a diverse range of Active Pharmaceutical Ingredients (APIs) across various therapeutic segments.
They generate revenue by selling these APIs to pharmaceutical companies for use in their finished drug formulations, leveraging their R&D capabilities and manufacturing facilities.

FY26 (standalone): revenue ₹828 cr, up 19% from ₹696 cr in FY25; net profit ₹209 cr, up 11% from ₹188 cr in FY25.
FY26 (standalone): operating cash flow ₹186 cr (0.9× net profit); debt/equity 0.00×.
Latest quarter to Jun 2026 (standalone): revenue ₹190 cr (up 31% year on year); net profit ₹24.0 cr.

The company has historically had a high share of revenue from its top 10 customers, though it plans to reduce…
Export sales as a percentage of revenue have shown fluctuations

Supriya Lifescience Limited

Research at a glance

Supriya Lifescience Limited FAQs

Supriya Lifescience Limited

Business at a Glance

What Looks Strong

What to Watch

Research at a glance

Supriya Lifescience Limited FAQs

Related paths

Related insights

BLUEJET

ZOTA

CONCORDBIO

How to Use Anvest Intelligence Effectively: 10 Practical AI Stock Research Prompts

Business at a Glance

What Looks Strong

What to Watch